IDEAYA Biosciences (NASDAQ:IDYA) Rating Lowered to “Sell” at Wall Street Zen

IDEAYA Biosciences (NASDAQ:IDYA) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “sell” rating in a research note issued on Saturday.

Several other equities research analysts have also recently weighed in on IDYA. Mizuho upped their price target on IDEAYA Biosciences from $44.00 to $46.00 and gave the company an “outperform” rating in a research report on Tuesday, November 11th. Citigroup boosted their price objective on shares of IDEAYA Biosciences from $64.00 to $65.00 and gave the company a “buy” rating in a research note on Thursday. UBS Group began coverage on shares of IDEAYA Biosciences in a report on Wednesday, January 7th. They set a “buy” rating and a $50.00 target price on the stock. Guggenheim reissued a “buy” rating and issued a $50.00 price target on shares of IDEAYA Biosciences in a report on Wednesday, February 18th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of IDEAYA Biosciences in a research report on Wednesday. Fifteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $48.69.

IDEAYA Biosciences Price Performance

Shares of IDYA stock opened at $31.98 on Friday. The stock has a market capitalization of $2.81 billion, a price-to-earnings ratio of -24.41 and a beta of 0.10. The company’s fifty day simple moving average is $34.19 and its two-hundred day simple moving average is $30.60. IDEAYA Biosciences has a 1 year low of $13.45 and a 1 year high of $39.28.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings results on Tuesday, February 17th. The company reported ($0.94) earnings per share for the quarter, beating the consensus estimate of ($1.03) by $0.09. The company had revenue of $21.75 million during the quarter, compared to analysts’ expectations of $5.95 million. During the same quarter last year, the firm posted ($1.49) earnings per share. IDEAYA Biosciences’s revenue for the quarter was up 55.7% compared to the same quarter last year. Equities research analysts anticipate that IDEAYA Biosciences will post -3.07 EPS for the current year.

Hedge Funds Weigh In On IDEAYA Biosciences

Large investors have recently modified their holdings of the company. Farther Finance Advisors LLC lifted its position in IDEAYA Biosciences by 171.1% in the fourth quarter. Farther Finance Advisors LLC now owns 919 shares of the company’s stock valued at $32,000 after purchasing an additional 580 shares during the last quarter. ANTIPODES PARTNERS Ltd boosted its position in IDEAYA Biosciences by 49.4% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,150 shares of the company’s stock valued at $40,000 after buying an additional 380 shares during the period. Aster Capital Management DIFC Ltd bought a new stake in IDEAYA Biosciences in the 3rd quarter worth $38,000. Global Retirement Partners LLC purchased a new position in shares of IDEAYA Biosciences in the fourth quarter valued at about $61,000. Finally, Abich Financial Wealth Management LLC bought a new position in shares of IDEAYA Biosciences during the third quarter valued at about $58,000. 98.29% of the stock is owned by hedge funds and other institutional investors.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.